You've heard about Ozempic. Probably Wegovy, Mounjaro, Zepbound. Maybe someone you know is on one of them. What you've probably heard less about is the underlying biology: what GLP-1 actually is, why this class of drugs works the way it does, and what the research beyond weight loss is starting to show.
GLP-1 is a hormone your body already makes
GLP-1 stands for glucagon-like peptide-1. It's a short peptide hormone produced in your gut, specifically by cells in the small intestine and colon, in response to eating. When you eat a meal, your gut releases GLP-1 into the bloodstream, and it does several things at once.
- It signals the pancreas to release insulin (which lowers blood sugar) and to suppress glucagon (which raises blood sugar). Net effect: more controlled blood glucose after a meal.
- It slows gastric emptying, meaning food moves more slowly from your stomach into your intestines. This extends the feeling of fullness.
- It signals the brain, particularly areas involved in appetite regulation, that you've eaten and don't need more food. This is the satiety signal that's gotten so much attention.
In short, GLP-1 is a natural brake on overeating and blood sugar spikes. The problem, for people with type 2 diabetes or obesity, is that this system often doesn't work efficiently enough: GLP-1 isn't released in sufficient amounts, the signals don't land hard enough, or the brain's response is blunted.
What GLP-1 receptor agonists actually do
A GLP-1 receptor agonist is a drug that binds to the same receptors that your natural GLP-1 binds to, but it does so more powerfully and for much longer. Your body's natural GLP-1 has a half-life of a few minutes. Semaglutide, for example, has a half-life of about a week. It's engineered to resist breakdown and to stay active far longer than the hormone it mimics.
The result is a sustained version of the signals your body already knows how to process: reduced appetite, better blood sugar control, and slower gastric emptying.
The approved drugs: semaglutide and tirzepatide
Semaglutide is the most widely known compound in this class. It's a GLP-1 receptor agonist approved by the FDA under two brand names: Ozempic (for type 2 diabetes management) and Wegovy (for chronic weight management in adults with obesity or weight-related conditions). The same molecule, different approved indications and dosing regimens.
The STEP trial program, which underpinned Wegovy's approval, showed average weight loss of around 15% of body weight over 68 weeks at the highest dose, compared to about 2% in the placebo group. Those are large effects by the standards of obesity pharmacology.
Tirzepatide (Mounjaro for diabetes, Zepbound for weight management) is the next generation. It's a dual agonist: it targets both the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide, another gut hormone involved in insulin regulation). Whether the dual mechanism is the reason for tirzepatide's stronger effects, or whether it simply reflects higher effective doses, is still debated. In the SURMOUNT trials, tirzepatide produced average weight loss of around 20% of body weight at the highest dose.
Research-stage compounds: what's coming
The class is still evolving. Two compounds worth understanding are in late-stage development.
Retatrutide is a triple agonist targeting GLP-1, GIP, and the glucagon receptor. Phase 2 results published in the New England Journal of Medicine in 2023 showed average weight loss approaching 24% at 48 weeks. Glucagon receptor activation may enhance fat burning beyond what the dual-agonist approach captures. Phase 3 trials are ongoing.
Cagrilintide takes a different approach. It's an amylin analog (amylin is another gut hormone that signals satiety) being studied in combination with semaglutide under the name CagriSema. Early results suggest additive weight loss effects by targeting two distinct satiety pathways simultaneously.
What the research actually shows
The cardiovascular data on this class is striking. The SELECT trial, published in 2023, showed that semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in people with established cardiovascular disease and overweight or obesity who did not have diabetes. Over 17,000 participants, hard endpoints. The FDA approved a cardiovascular risk-reduction indication for Wegovy in 2024.
There's also emerging data on metabolic liver disease (previously called non-alcoholic fatty liver disease). Both semaglutide and tirzepatide show meaningful reductions in liver fat in early trials.
The cognitive data is earlier and should be read carefully. Some observational studies suggest lower rates of dementia in GLP-1 users, and there are mechanistic reasons to think these drugs could affect neuroinflammation. But these are hypothesis-generating findings, not established effects. Randomized trials are underway.
The honest caveats
The GLP-1 story is real and the effects are large by pharmacological standards. But several caveats deserve direct attention.
Side effects are common, especially in the early weeks. Nausea, vomiting, and diarrhea affect a substantial portion of patients during dose escalation. Most cases diminish over time, but a meaningful minority discontinue treatment because of them. Rare but serious concerns include pancreatitis risk (causality in humans remains debated) and possible thyroid C-cell effects seen in rodent studies, which led to a boxed warning in the prescribing information.
Muscle loss is a legitimate concern. Weight lost in these trials includes both fat and lean mass. Some analyses suggest 25-40% of total weight lost may be lean mass, similar to other forms of caloric restriction. Whether that's clinically significant long-term, and whether resistance exercise or higher protein intake can mitigate it, is still being studied.
What happens when you stop is becoming clear: most of the weight returns within a year or two of discontinuation, for most patients. This positions these drugs as chronic medications for a chronic condition.
Cost and access remain serious barriers. List prices in the US run to hundreds of dollars per month. Insurance coverage is inconsistent. The compounded semaglutide market that emerged during shortage periods created access for some patients but also real quality-control concerns. Biosimilars and generic pathways are years away.
Why this class matters for understanding peptides broadly
The GLP-1 drugs work by mimicking a naturally occurring peptide hormone through a synthetic analog engineered for longer duration and receptor potency. Their success is proof of concept: find the body's natural signaling molecule, understand the receptor it binds, and build a version that delivers that signal more consistently. That's the same framework behind many research peptides still in development, and it's why this class matters beyond just weight loss.
Where to go from here
If you want a broader foundation for understanding how peptides work as a class, the What Are Peptides, Really? guide covers the underlying biology. If you're specifically interested in how approved drugs like semaglutide differ legally and evidentially from research peptides, the Research Peptides vs. FDA-Approved Compounds guide goes into that distinction in detail.